10-Q: Corvus Pharma Advances Pipeline, Reports Q2 2025 Results

Corvus Pharmaceuticals reported a net income for the first six months of 2025 driven by a warrant revaluation gain, while advancing its lead drug candidates soquelitinib and ciforadenant in clinical trials.

Summary

• Net income of $7.195 million for the six months ended June 30, 2025, compared to a net loss of $9.963 million for the same period in 2024, primarily due to a $27.141 million non-operating gain from the change in fair value of warrant liability.
• Net loss of $7.998 million for the three months ended June 30, 2025, compared to $4.262 million for the same period in 2024.
• Accumulated deficit reached $389.8 million as of June 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $74.4 million as of June 30, 2025, which management believes will fund planned operations for at least 12 months from the filing date (into Q4 2026).
• Research and development expenses increased to $15.326 million for the six months ended June 30, 2025, from $8.189 million in the prior year period, driven by higher drug manufacturing and clinical trial costs for soquelitinib.
• General and administrative expenses increased to $4.856 million for the six months ended June 30, 2025, from $3.999 million in the prior year period.
• Soquelitinib's Phase 1 atopic dermatitis trial showed a mean EASI reduction of 64.8% for cohort 3 (200 mg BID) at day 28, compared to 34.4% for placebo.
• In the atopic dermatitis trial, 4 of 8 evaluable patients in cohort 3 achieved a 4-point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) score at day 28.
• Soquelitinib's Phase 1/1b clinical trial in relapsed/refractory T-cell lymphomas (PTCL) reported an objective response rate (ORR) of 39% (9 of 23 evaluable patients), including 6 complete responses (CRs) and 3 partial responses (PRs), with a median progression-free survival (PFS) of 6.2 months.
• Enrollment has been completed for the ciforadenant Phase 1b/2 clinical trial in metastatic RCC, which met its interim efficacy threshold.

Sentiment

Score: 7

Explanation: The company reported a net income for the six-month period, albeit largely due to a non-operating gain from warrant revaluation. More importantly, the clinical trial data for soquelitinib in atopic dermatitis and T-cell lymphoma show promising efficacy and safety profiles, with favorable comparisons to existing therapies. The cash position provides a runway into Q4 2026, which is positive, though significant future capital raises are still required. The progress in the pipeline and positive clinical readouts outweigh the continued operational losses and future funding needs, indicating a generally positive outlook for pipeline advancement.

Positives

• Net income of $7.195 million for the six months ended June 30, 2025, primarily due to a $27.141 million non-operating gain from warrant liability revaluation.
• Cash, cash equivalents, and marketable securities of $74.4 million as of June 30, 2025, providing a funding runway into Q4 2026.
• Soquelitinib Phase 1 atopic dermatitis trial demonstrated clinically meaningful efficacy, with cohort 3 showing a 64.8% mean EASI reduction at day 28 and 50% of evaluable patients achieving a 4-point PP-NRS reduction.
• Soquelitinib was well-tolerated in the atopic dermatitis trial with no dose-limiting toxicities or significant laboratory abnormalities.
• Soquelitinib Phase 1/1b data in PTCL showed a 39% objective response rate (6 CRs, 3 PRs) and an 18-month PFS rate of 30%, which compares favorably to belinostat or pralatrexate (<20%).
• Soquelitinib received FDA Fast Track designation for relapsed or refractory PTCL and Orphan Drug Designation for T-cell lymphoma.
• Ciforadenant Phase 1b/2 clinical trial in metastatic RCC met its interim efficacy threshold, leading to continued enrollment and completion.
• Preclinical data for soquelitinib published in npj Drug Discovery supports its selective ITK inhibition, Th1 skewing, activation of cytotoxic killer cells, and reduction of T-cell exhaustion, suggesting broad potential in solid and hematological cancers.

Negatives

• Continued operating losses, with a net loss of $7.998 million for the three months ended June 30, 2025.
• Accumulated deficit of $389.8 million as of June 30, 2025, indicating a history of significant losses.
• Increased research and development expenses by $7.137 million for the six months ended June 30, 2025, compared to the prior year, reflecting higher drug manufacturing and clinical trial costs.
• Increased general and administrative expenses by $0.857 million for the six months ended June 30, 2025, compared to the prior year.
• The company will need to raise substantial additional capital to fund operations beyond Q4 2026 and complete ongoing/planned clinical trials.

Risks

• Need for substantial additional financing to achieve goals, with no assurance of obtaining it on acceptable terms or at all, potentially forcing delays or termination of product development.
• Uncertainty of clinical drug development outcomes; preclinical and early clinical trial results are not predictive of future results, and product candidates may fail in later stages.
• Potential for termination, suspension, or delays in clinical trials due to various factors, including regulatory holds, enrollment difficulties, or adverse side effects, leading to increased costs and delayed revenue.
• Risk of serious complications or side effects from product candidates, which could lead to discontinuation of programs, denial of regulatory approval, or post-approval withdrawal.
• Reliance on third parties for clinical trials, manufacturing, research, and preclinical testing, with risks of non-performance, missed deadlines, or non-compliance with regulatory standards.
• Inability to successfully scale-up manufacturing of product candidates in sufficient quality and quantity.
• Competition from larger, better-funded pharmaceutical companies and other research institutions, potentially with more effective technologies or faster development.
• Market opportunities for product candidates may be limited to specific patient populations (e.g., later-line therapies) and may be smaller than estimated.
• Inability to obtain or maintain adequate coverage and reimbursement for approved products from government and private payors.
• Exposure to changes in U.S. and foreign healthcare laws and regulations, including price controls and reforms (e.g., Inflation Reduction Act, One Big Beautiful Bill Act), which could adversely affect profitability.
• Risks related to intellectual property, including challenges to patents, inability to protect trade secrets, and potential infringement claims by third parties.
• Volatility of common stock price due to various factors, including clinical trial results, regulatory approvals, and general market conditions.
• Potential limitations on the use of net operating loss carryforwards and other tax attributes due to ownership changes.
• Risks associated with operating in foreign markets, including additional regulatory burdens and reduced intellectual property protection.
• Vulnerability of information technology systems to security breaches, potentially disrupting product development and leading to financial losses or litigation.
• Dependence on key personnel, particularly the President and CEO, and the ability to attract and retain qualified management and scientific staff.

Future Outlook

Management believes that the Company's cash, cash equivalents and marketable securities as of June 30, 2025 will be sufficient to fund planned operations for a period of at least 12 months from the date these condensed consolidated financial statements are issued (into Q4 2026). The Company expects to initiate planning for a Phase 2 clinical trial in atopic dermatitis by the end of 2025, enrolling approximately 200 patients. The Company will need to raise additional capital through private and public equity offerings, debt financings, and potential future collaboration, license, and development agreements to fund operations beyond the current runway and complete ongoing and planned clinical trials.

Management Comments

• Management expects operating losses to continue for the foreseeable future.
• Management believes that the Company's cash, cash equivalents and marketable securities as of June 30, 2025 will be sufficient to fund the Company's planned operations for a period of at least 12 months from the date these condensed consolidated financial statements are issued.
• To fund the Company's planned operations, the Company will need to raise additional capital.
• The Company intends to raise additional capital through private and public equity offerings, including its at-the-market offering program, debt financings and potential future collaboration, license and development agreements.
• The Company expects that the trial will be placebo controlled and we intend to enroll a total of approximately 200 patients randomized in to four cohorts comparing different dosing regimens of soquelitinib to placebo.
• We are planning a Phase 1b/2 clinical trial, in collaboration with the Kidney Cancer Research Consortium, of soquelitinib in solid tumors in patients with renal cell cancer who have failed checkpoint inhibitor therapy.
• We are waiting to initiate a potential Phase 2 randomized clinical trial for mupadolimab in order to prioritize the development of our other product candidates.

Industry Context

The biopharmaceutical industry is highly competitive and capital-intensive, with significant risks associated with drug development, regulatory approval, and commercialization. Corvus Pharmaceuticals operates within the oncology and immunology therapeutics fields, facing competition from larger, well-funded companies and research institutions. The company's strategy of leveraging research and development capabilities to evaluate product candidates in diverse disease areas with unmet needs aligns with broader industry trends focusing on targeted therapies and immune modulation. The regulatory landscape, including the Inflation Reduction Act and the newly enacted One Big Beautiful Bill Act, introduces further cost-containment pressures and potential changes to reimbursement models, impacting the commercial viability of new drugs.

Comparison to Industry Standards

• Soquelitinib's 18-month progression-free survival (PFS) rate of 30% in relapsed/refractory PTCL compares favorably to less than 20% for existing standard-of-care chemotherapies like belinostat or pralatrexate.
• The EASI 75 and IGA 0 or 1 endpoints achieved in the soquelitinib atopic dermatitis trial are considered clinically meaningful and approvable endpoints by the U.S. Food and Drug Administration (FDA) and have been used in clinical trials for other FDA-approved treatments for atopic dermatitis.

Related Party Transactions

• In the May 6, 2024 registered direct offering, related parties purchased common stock, pre-funded warrants, and common warrants, including OrbiMed Advisors LLC ($2,499,856), Puissance Capital Management ($1,500,000), Richard A. Miller, M.D. ($1,000,000), and William B. Jones, Ph.D. ($34,624).
• During the three months ended June 30, 2025, all common warrants sold to related parties in the May 2024 offering were exercised, resulting in aggregate proceeds of $4,960,000 from related parties (including $2,935,135 from Puissance Capital Management, $1,956,756 from Richard A. Miller, M.D., and $67,750 from William B. Jones, Ph.D.).
• OrbiMed Advisors LLC exercised its warrants on a cashless basis, resulting in the company withholding 1,176,332 shares and issuing 221,352 shares.
• The company recorded approximately $137,000 in clinical trial expenses with ICON plc during the three months ended June 30, 2025, where Linda S. Grais, M.D., J.D., a board member, is a non-executive director.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings (e.g., ATM program) and stock price volatility due to clinical trial outcomes and funding needs.
• Employees are subject to intense competition for qualified personnel, particularly in the San Francisco Bay Area, and the company's ability to attract and retain talent is crucial for business objectives.
• Patients with T-cell lymphomas and atopic dermatitis may benefit from the advancement of soquelitinib, which has shown promising interim clinical results.
• Creditors may be impacted by the company's need for debt financings, which could impose covenants restricting operations.
• Suppliers and contract manufacturers are critical for drug substance and product supply, and any disruptions could seriously harm operations.

Next Steps

• Initiate planning for a Phase 2 clinical trial for soquelitinib in atopic dermatitis by the end of 2025, enrolling approximately 200 patients.
• Continue the registrational Phase 3 clinical trial for soquelitinib in relapsed/refractory PTCL.
• Plan a Phase 1b/2 clinical trial of soquelitinib in solid tumors (renal cell cancer) in collaboration with the Kidney Cancer Research Consortium.
• Continue to advance next-generation ITK inhibitor preclinical product candidates.
• Angel Pharmaceuticals to continue development of mupadolimab in China.
• Need to raise additional capital to fund operations beyond Q4 2026.

Key Dates

Recommendation

While Corvus Pharmaceuticals reported a net income for the six-month period, this was primarily due to a non-operating gain from warrant revaluation, and the company continues to incur significant operating losses. The positive interim clinical data for soquelitinib in both T-cell lymphoma and and atopic dermatitis are encouraging and provide a strong basis for future development, including a planned Phase 2 trial in atopic dermatitis and an ongoing Phase 3 trial in PTCL. The current cash runway into Q4 2026 is a positive, but the company explicitly states the need for substantial additional capital to complete its clinical programs. Given the early to mid-stage nature of its pipeline, the significant future funding requirements, and the inherent risks of clinical development and regulatory approval in the biopharmaceutical sector, a 'hold' recommendation is appropriate. Investors should monitor the progress of clinical trials and future financing activities closely before considering further investment.

Keywords

Biopharmaceutical, Clinical-stage, Oncology, Immunology, T-cell Lymphoma, Atopic Dermatitis, ITK Inhibitor, Adenosine A2A Receptor Antagonist, Anti-CD73 Antibody, Soquelitinib, Ciforadenant, Mupadolimab, Drug Development, Clinical Trials, SEC Filing, Biotech, Pharmaceuticals, Investment